Lactate dehydrogenase inhibition: Exploring possible applications beyond cancer treatment

Future Medicinal Chemistry

Volumn 8, Issue 6, 2016, Pages 713-725

  Di Stefano, Giuseppina ^a   Manerba, Marcella ^a   Di Ianni, Lorenza ^a   Fiume, Luigi ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

cancer cell metabolism; epilepsy; glycolysis; immune inflammatory diseases; lactate dehydrogenase; virus induced metabolic changes

Indexed keywords

ENZYME INHIBITOR; LACTATE DEHYDROGENASE; LACTATE DEHYDROGENASE INHIBITOR; UNCLASSIFIED DRUG; ANTICONVULSIVE AGENT; ANTIINFLAMMATORY AGENT; ANTINEOPLASTIC AGENT;

CANCER THERAPY; CELL METABOLISM; ENERGY METABOLISM; ENZYME ACTIVITY; ENZYME INHIBITION; EPILEPSY; GLYCOLYSIS; HUMAN; INFLAMMATORY DISEASE; PRIORITY JOURNAL; REVIEW; ANTAGONISTS AND INHIBITORS; CHEMISTRY; DRUG DEVELOPMENT; ENZYMOLOGY; IMMUNOLOGY; INFLAMMATION; METASTASIS; NEOPLASMS; OXIDATION REDUCTION REACTION; TUMOR CELL LINE; VIRAL PHENOMENA AND FUNCTIONS;

ANTI-INFLAMMATORY AGENTS; ANTICONVULSANTS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DRUG DISCOVERY; ENERGY METABOLISM; EPILEPSY; GLYCOLYSIS; HUMANS; INFLAMMATION; L-LACTATE DEHYDROGENASE; NEOPLASM METASTASIS; NEOPLASMS; OXIDATION-REDUCTION; VIRUS PHYSIOLOGICAL PHENOMENA;

EID: 84966669709     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.16.10     Document Type: Review

References (95)

1. Everse J, Kaplan NO. Lactate dehydrogenases: structure and function. Adv. Enzymol. Relat. Areas Mol. Biol. 37, 61-133 (1973).
2. Markert CL, Shaklee JB, Whitt GS. Evolution of a gene. Multiple genes for LDH isozymes provide a model of the evolution of gene structure, function, and regulation. Science 189, 102-114 (1975).
3. Fiume L, Manerba M, Vettraino M et al. Inhibition of lactate dehydrogenase activity as an approach to cancer therapy. Future Med. Chem. 6, 429-445 (2014).
4. Petrelli F, Cabiddu M, Coinu A et al. Prognostic role of lactate dehydrogenase in solid tumors: A systematic review and meta-analysis of 76 studies. Acta Oncol. 54, 961-970 (2015).
5. Sugden MC, Holness MJ. Recent advances in mechanisms regulating glucose oxidation at the level of the pyruvate dehydrogenase complex by PDKs. Am. J. Physiol. Endocrinol. Metab. 284, E855-E862 (2003).
6. Gillies RJ, Robey I, Gatenby RA. Causes and consequences of increased glucose metabolism of cancers. J. Nucl. Med. 49, S24-S42 (2008).
7. Granchi C, Bertini S, Macchia M et al. Inhibitors of lactate dehydrogenase isoforms and their therapeutic potentials. Curr. Med. Chem. 17, 672-697 (2010).
8. Augoff K, Hryniewicz-Jankowska A, Tabola R. Lactate dehydrogenase 5: an old friend and a new hope in the war on cancer. Cancer Lett. 358, 1-7 (2015).
9. Pecqueur C, Oliver L, Oizel K et al. Targeting metabolism to induce cell death in cancer cells and cancer stem cells. Int. J. Cell Biol. 2013, 805975 (2013).
10. Zaho Y, Butler EB, Tan M. Targeting cellular metabolism to improve cancer therapeutics. Cell Death Dis. 4, e532 (2013).
11. Warburg O. The Metabolism Of Tumours. Translated by Dickens F. Constable, London, UK (1930).
12. DeBerardinis RJ, Lum JJ, Hatzivassiliou G et al. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab. 7, 11-20 (2008).
13. Rani R, Kumar V. Recent update on human lactate dehydrogenase enzyme 5 (hLDH5) inhibitors: A promising approach for cancer chemotherapy. J. Med. Chem. 59, 487-496 (2016).
14. Wang ZY, Loo TY, Shen JG et al. LDH-A silencing suppresses breast cancer tumorigenicity through induction of oxidative stress mediated mitochondrial pathway apoptosis. Breast Cancer Res. Treat. 131, 791-800 (2012).
15. Arseneault R, Chien A, Newington JT et al. Attenuation of LDHA expression in cancer cells leads to redox-dependent alterations in cytoskeletal structure and cell migration. Cancer Lett. 338, 255-266 (2013).
16. Manerba M, Di Ianni L, Fiume L et al. Lactate dehydrogenase inhibitors sensitize lymphoma cells to cisplatin without enhancing the drug effects on immortalized normal lymphocytes. Eur. J. Pharm. Sci. 74, 95-102 (2015).
17. Vettraino M, Manerba M, Govoni M et al. Galloflavin suppresses lactate dehydrogenase activity and causes MYC downregulation in Burkitt lymphoma cells via NAD/NADH-dependent inhibition of sirtuin-1. Anti-Cancer Drugs 24, 862-870 (2013).
18. Valvona CJ, Filmore HL, Nunn PB et al. The regulation and function of lactate dehydrogenase A: therapeutic potential in brain tumour. Brain Pathol. 26, 3-17 (2016).
19. Dai RP, Yu FX, Goh SR et al. Histone 2B (H2B) expression is confined to a proper NAD+/NADH redox status. J. Biol. Chem. 283, 26894-26901 (2008).
20. Sirven JI. Epilepsy: A spectrum disorder. Cold Spring Harb. Perspect. Med. 5, a022848 (2015).
21. Lennox WG, Cobb S. Epilepsy from the standpoint of physiology and treatment. Medicine 7, 105-290 (1928).
22. Peterman M. The ketogenic diet in the treatment of epilepsy: A preliminary report. Am. J. Dis. Child. 28, 28-33 (1924).
23. Geyelin HR. Fasting as a method for treating epilepsy. Med. Rec. 99, 1037-1039 (1921).
24. Ma W, Berg J, Yellen GS. Ketogenic diet metabolites reduce firing in central neurons by opening K(ATP) channels. J. Neurosci. 27, 3618-3625 (2007).
25. Masino SA, Li T, Theofilas P et al. A ketogenic diet suppresses seizures in mice through adenosine A1 receptors. J. Clin. Invest. 121, 2679-83 (2011).
26. Rho JM. How does the ketogenic diet induce anti-seizure effects? Neurosci. Lett. doi:10.1016/j.neulet.2015.07.034 (2015) (Epub ahead of print).
27. Gallagher CN, Carpenter KL, Grice P et al. The human brain utilizes lactate via the tricarboxylic acid cycle: A 13C-labelled microdialysis and high-resolution nuclear magnetic resonance study. Brain 132, 2839-2849 (2009).
28. Sada N, Lee S, Katsu T et al. Targeting LDH enzymes with a stiripentol analog to treat epilepsy. Science 347, 1362-1367 (2015).
29. Papacostantinou J, Colowick SP. The role of glycolysis in the growth of tumor cells. I. Effects of oxamic acid on the metabolism of Ehrlich tumor cells in vitro. J. Biol. Chem. 236, 278-284 (1961).
30. Brigo F, Storti M, Igwe SC. Stiripentol for focal refractory epilepsy. Cochrane Database Syst. Rev. 10, CD009887 (2015).
31. Warburg O, Gawehn K, Geissler AW. Metabolism of leukocytes. Z Naturforsch. B 13B, 515-516 (1958).
32. Palsson-McDermott EM, O'Neill LAJ. The Warburg effect then and now: from cancer to inflammatory diseases. Bioessays 35, 965-973 (2013).
33. Hume DA. The many alternative faces of macrophage activation. Front. Immunol. 6, 370 (2015).
34. Freemerman AJ, Johnson AR, Sacha GN et al. Metabolic reprogramming of macrophages: glucose transporter 1 (GLUT1)-mediated glucose metabolism drives a proinflammatory phenotype. J. Biol. Chem. 289, 7884-7896 (2014).
35. Tornatore L, Thotakura AK, Bennet J et al. The nuclear factor kappa B signaling pathway: integrating metabolism with inflammation. Trends Cell Biol. 22, 557-566 (2012).
36. Moretti M, Bennet J, Tornatore L et al. Cancer: NF-kB regulates energy metabolism. Int. J. Biochem. Cell Biol. 44, 2238-2243 (2012).
37. MacIver NJ, Michalek RD, Rathmell JC. Metabolic regulation of T lymphocytes. Annu. Rev. Immunol. 31, 259-283 (2013).
38. Palmer CS, Ostrowski M, Balderson B et al. Glucose metabolism regulates T cell activation, differentiation and functions. Front. Immunol. 6, 1 (2015).
39. Dang CV, Le A, Gao P. MYC-induced cancer cell energy metabolism and therapeutic opportunities. Clin. Cancer Res. 15, 6479-6483 (2009).
40. Michalek RD, Gerriets VA, Jacobs SR et al. Cutting edge: distinct glycolytic and lipid oxidation metabolic programs are essential for effector and regulatory CD4+ T cell subsets. J. Immunol. 186, 3299-3303 (2011).
41. Delgoffe GM, Pollizzi KN, Waickman AT et al. The kinase mTOR regulates the differentiation of helper T cells through the selective activation of signaling by mTORC1 and mTORC2. Nat. Immunol. 12, 295-303 (2011).
42. Dang EV, Barbi J, Yang HY et al. Control of T(H)17/T(reg) balance by hypoxia-inducible factor 1. Cell 146, 772-784 (2011).
43. Marín-Hernández A, Gallardo-Pérez JC, Ralph SJ et al. HIF-1alpha modulates energy metabolism in cancer cells by inducing over-expression of specific glycolytic isoforms. Mini Rev. Med. Chem. 9, 1084-1101 (2009).
44. Peters A, Lee Y, Kuchroo VK. The many faces of Th17 cells. Curr. Opin. Immunol. 23, 702-706 (2011).
45. Chang CH, Curtis JD, Maggi LB et al. Posttranscriptional control of T cell effector function by aerobic glycolysis. Cell 153, 1239-1251 (2013).
46. Ostroukhova M, Goplen N, Karim MZ et al. The role of lowlevel lactate production in airway inflammation in asthma. Am. J. Physiol. Lung Cell. Mol. Physiol. 302, L300-L307 (2012).
47. Shi LZ, Wang R, Huang G et al. HIF1α-dependent glycolytic pathway orchestrates ametabolic checkpoint for the differentiation of TH17 and Treg cells. J. Exp. Med. 208, 1367-1376 (2011).
48. Bian L, Josefsson E, Jonsson IM et al. Dichloroacetate alleviates development of collagen II-induced arthritis in female DBA/1 mice. Arthritis Res. Ther. 11, R132 (2009).
49. Tannahill GM, Iraci N, Gaude E et al. Metabolic reprogramming of mononuclear phagocytes in progressive multiple sclerosis. Front. Immunol. 6, 106 (2015).
50. Lassmann H, vanHorssen J, Mahad D. Progressive multiple sclerosis pathology and pathogenesis. Nat. Rev. Neurol. 8, 647-656 (2012).
51. Trebst C, Sorensen TL, Kivisakk P et al. CCR1+/CCR5+ mononuclear phagocytes accumulate in the central nervous system of patients with multiple sclerosis. Am. J. Pathol. 159, 1701-1710 (2001).
52. Grahame Hardie D. AMP-activated protein kinase: A key regulator of energy balance with many roles in human disease. J. Intern. Med. 276, 543-559 (2014).
53. Nath N, Khan M, Paintlia MK et al. Metformin attenuated the autoimmune disease of the central nervous system in animal models of multiple sclerosis. J. Immunol. 182, 8005-8014 (2009).
54. Jeong SM, Haigis MC. Sirtuins in cancer: A balancing act between genome stability and metabolism. Mol. Cells 38, 750-758 (2015).
55. Pelicano H, Martin DS, Xu RH et al. Glycolysis inhibition for anticancer treatment. Oncogene 25, 4633-4646 (2006).
56. Das L, Vinayak M. Long term effect of curcumin in regulation of glycolytic pathway and angiogenesis via modulation of stress activated genes in prevention of cancer. PLoS ONE 9, e99583 (2014).
57. Arora R, Schmitt D, Karanam B et al. Inhibition of the Warburg effect with a natural compound reveals a novel measurement for determining the metastatic potential of breast cancer. Oncotarget 6, 662-678 (2015).
58. Husain Z, Huang Y, Seth P et al. Tumor-derived lactate modifies antitumor immune response: effect on myeloidderived suppressor cells and NK cells. J. Immunol. 191, 1486-1495 (2013).
59. Crane CA, Austgen K, Haberthur K et al. Immune evasion mediated by tumor-derived lactate dehydrogenase induction of NKG2D ligands on myeloid cells in glioblastoma patients. Proc. Natl Acad. Sci. USA 111, 12823-12828 (2014).
60. Lewis VJ, Scott LV. Nutritional requirements for the production of herpes simplex virus. I. Influence of glucose and glutamine of herpes simplex virus production by HeLa cells. J. Bacteriol. 83, 475-482 (1962).
61. Ludwig H, Rott R. Effect of 2-deoxy-D-glucose on herpesvirus-induced inhibition of cellular DNA synthesis. J. Virol. 16, 217-221 (1975).
62. Sanchez EL, Lagunoff M. Viral activation of cellular metabolism. Virology 479-480, 609-618 (2015).
63. Munger J, Bajad SU, Coller HA et al. Dynamics of the cellular metabolome during human cytomegalovirus infection. PLoS Pathog. 2, e132 (2006).
64. McArdle J, Schafer XL, Munger J. Inhibition of calmodulindependent kinase blocks human cytomegalovirus-induced glycolytic activation and severely attenuates production of viral progeny. J. Virol. 85, 705-714 (2011).
65. Yu Y, Maguire TG, Alwine JC. Human cytomegalovirus activates glucose transporter 4 expression to increase glucose uptake during infection. J. Virol. 85, 1573-1580 (2011).
66. Yu Y, Maguire TG, Alwine JC. ChREBP, a glucose-responsive transcriptional factor, enhances glucose metabolism to support biosynthesis in human cytomegalovirus-infected cells. Proc. Natl Acad. Sci. USA 111, 1951-1956 (2014).
67. Soroceanu L, Cobbs CS. Is HCMV a tumor promoter? Virus Res. 157, 193-203 (2011).
68. Xiao L, Hu ZY, Dong X et al. Targeting Epstein-Barr virus oncoprotein LMP1-mediated glycolysis sensitizes nasopharyngeal carcinoma to radiationtherapy. Oncogene 33, 4568-4578 (2014).
69. Delgado T, Carroll PA, Punjabi AS et al. Induction of the Warburg effect by Kaposi's sarcoma herpesvirus is required for the maintenance of latently infected endothelial cells. Proc. Natl. Acad. Sci. USA 107, 10696-10701 (2010).
70. Fukuda M, Longnecker R. Epstein-Barr virus latent membrane protein 2A mediates transformation through constitutive activation of the Ras/PI3-K/Akt pathway. J. Virol. 81, 9299-9306 (2007).
71. Wakisaka N, Kondo S, Yoshizaki T et al. Epstein-Barr virus latent membrane protein 1 induces synthesis of hypoxiainducible factor 1 alpha. Mol. Cell Biol. 24, 5223-5234 (2004).
72. Ousset M, Bouquet F, Fallone F et al. Loss of ATM positively regulates the expression of hypoxia inducible factor 1 (HIF-1) through oxidative stress: role in the physiopathology of the disease. Cell Cycle 9, 2814-2822 (2010).
73. Yogev O, Lagos D, Enver T et al. Kaposi's sarcoma herpesvirus microRNAs induce metabolic transformation of infected cells. PLoS Pathog. 10, e1004400 (2014).
74. Thai M, Graham NA, Braas D et al. Adenovirus E4ORF1-induced Myc activation promotes host cell anabolic glucose metabolism and virus replication. Cell Metab. 19, 694-701 (2014).
75. Ripoli M, D'Aprile A, Quarato G et al. Hepatitis C viruslinked mitochondrial dysfunction promotes hypoxiainducible factor 1 alpha-mediated glycolytic adaptation. J. Virol. 84, 647-660 (2010).
76. Diamond DL, Syder AJ, Jacobs JM et al. Temporal proteome and lipidome profiles reveal hepatitis C virusassociated reprogramming of hepatocellular metabolism and bioenergetics. PLoS Pathog. 6, e1000719 (2010).
77. Fontaine KA, Sanchez EL, Camarda R et al. Dengue virus induces and requires glycolysis for optimal replication. J. Virol. 89, 2358-2366 (2015).
78. Findlay JS, Ulaeto D. Semliki Forest virus and Sindbis virus, but not vaccinia virus, require glycolysis for optimal replication. J. Gen. Virol. 96, 2693-2696 (2015).
79. Dragovich PS, Fauber BP, Corson LB et al. Identification of substituted 2-thio-6-oxo-1,6-dihydropyrimidines as inhibitors of human lactate dehydrogenase. Bioorg. Med. Chem. Lett. 23, 3186-3194 (2013).
80. Fauber BP, Dragovich PS, Chen J et al. Identification of 3,6-disubstituted dihydropyrone as inhibitors of human lactate dehydrogenase. Bioorg. Med. Chem. Lett. 24, 5683-5687 (2014).
81. Xie H, Hanai J, Ren J et al. Targeting lactate dehydrogenase-A inhibits tumorigenesis and tumor progression in mouse models of lung cancer and impact tumor-initiating cells. Cell Metab. 19, 795-809 (2014).
82. Deiab S, Mazzio E, Eyunni S et al. 1,2,3,4,6-Penta-Ogallolylglucose within galla chinensis inhibits human LDH-A and attenuates cell proliferation in MDA-MB-231 breast cancer cells. Evid. Based Complement. Alternat. Med. 2015, 276946 (2015).
83. Rupiani S, Buonfiglio R, Manerba M et al. Identification of N-Acylhydrazone derivatives as novel lactate dehydrogenase A inhibitors. Eur. J. Med. Chem. 101, 63-70 (2015).
84. Chen CY, Feng Y, Chen JY et al. Identification of a potent inhibitor targeting human lactate dehydrogenase A and its metabolic modulation for cancer cell line. Bioorg. Med. Chem. Lett. 26, 72-75 (2016).
85. Billiard J, Dellison JB, Brain J et al. Quinoline 3-sulfonamides inhibit lactate dehydrogenase A and reverse aerobic glycolysis in cancer cells. Cancer Metab. 1, 19 (2013).
86. Buonfiglio R, Ferraro M, Falchi F et al. Collecting and assessing human lactate dehydrogenase-A conformations for structure-based virtual screening. J. Chem. Inf. Model. 53, 2792-2797 (2013).
87. Sun R, Li X, Li Y et al. Screening of novel inhibitors targeting lactate dehydrogenase A via four molecular docking strategies and dynamics simulations. J. Mol. Model. 21, 133-146 (2015).
88. Semenza GL, Jiang BH, Leung SW et al. Hypoxia response elements in aldolase A, enolase 1, and lactate dehydrogenase A gene promoters contain essential binding sites for hypoxiainducible factor 1. J. Biol. Chem. 51, 32529-32537 (1996).
89. Short ML, Haung D, Milkowski DM et al. Analysis of the rat lactate dehydrogenase A subunit gene promoter/regulatory region. Biochem. J. 304, 391-398 (1994).
90. Shim H, Dolde C, Lewis BC et al. c-Myc transactivation of LDH-A: implications for tumor metabolism and growth. Proc. Natl Acad. Sci. USA 94, 6658-6663 (1997).
91. Burke RE, Harris SC, McGuire WL. Lactate dehydrogenase in estrogen-responsive human breast cancer cells. Cancer Res. 38, 2773-2776 (1978).
92. Cui J, Shi M, Xie D et al. FOXM1 promotes the Warburg effect and pancreatic cancer progression via transactivation of LDHA expression. Clin. Cancer Res. 20, 2595-2606 (2014).
93. Boussouar F, Grataroli R, Ji J et al. Tumor necrosis factor-alpha stimulates lactate dehydrogenase A expression in porcine cultured sertoli cells: mechanisms of action. Endocrinology 140, 3054-3062 (1999).
94. Wang Z, Wang D, Hang S et al. Bioactivity-guided identification and cell signaling technology to delineate the lactate dehydrogenase A inhibition effects of Spatholobus suberectus on breast cancer. PLoS ONE 8, e56631 (2013).
95. Leidgens V, Seliger C, Jachnik B et al. Ibuprofen and diclofenac restrict migration and proliferation of human glioma cells by distinct molecular mechanisms. PLoS ONE 10, e0140613 (2015).